LIFEVANTAGE CORP Cash and Restricted Cash
LIFEVANTAGE CORP (LFVN) had Cash and Restricted Cash of $14.92 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-27
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.92M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12.48M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.18M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.09M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $14.92M 10-K · filed 2026-08-27 |
| 2026-03-31 | $12.48M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $10.18M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $13.09M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $20.20M 10-K · filed 2026-08-27 |
| 2025-03-31 | $22.47M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $21.59M 10-Q · filed 2026-02-04 |
| 2024-09-30 | $14.60M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $16.89M 10-K · filed 2026-08-27 |
| 2024-03-31 | $17.38M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $17.33M 10-Q · filed 2025-02-05 |
| 2023-09-30 | $18.41M 10-Q · filed 2024-10-29 |
| 2023-06-30 | $21.61M 10-K · filed 2025-09-04 |
| 2023-03-31 | $19.53M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $17.37M 10-Q · filed 2024-01-30 |
| 2022-09-30 | $17.62M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $20.19M 10-K · filed 2024-08-28 |
| 2022-03-31 | $17.80M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $20.17M 10-Q · filed 2023-02-02 |
| 2021-09-30 | $19.93M 10-Q · filed 2022-11-02 |
| 2021-06-30 | $23.17M 10-K · filed 2023-08-28 |
| 2021-03-31 | $18.95M 10-Q · filed 2022-05-03 |
| 2020-12-31 | $19.73M 10-Q · filed 2022-02-01 |
| 2020-09-30 | $17.96M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $22.14M 10-K · filed 2022-08-23 |
| 2020-03-31 | $13.46M 10-Q · filed 2021-04-29 |
| 2019-12-31 | $14.48M 10-Q · filed 2021-02-02 |
| 2019-09-30 | $13.01M 10-Q · filed 2020-11-03 |
| 2019-06-30 | $18.82M 10-K · filed 2022-08-23 |
| 2019-03-31 | $15.91M 10-Q · filed 2020-05-05 |
| 2018-12-31 | $18.99M 10-Q · filed 2020-01-28 |
| 2018-09-30 | $17.12M 10-Q · filed 2019-10-30 |
| 2018-06-30 | $16.65M 10-K · filed 2021-08-19 |
| 2018-03-31 | $13.95M 10-Q · filed 2019-05-01 |
| 2017-06-30 | $11.46M 10-K · filed 2020-08-18 |
| 2016-06-30 | $7.88M 10-K · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |